SCHEMBL26074299

SCHEMBL26074299

Cc1ccnc(C(=O)Nc2cc(C(C)(C)C)c(Cl)cc2F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.45
CSF1R P07333 1/20 0.45
CTSA P10619 1/20 0.41
ANO1 Q5XXA6 3/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
GRM4 Q14833 1/20 0.40
PYGL P06737 1/20 0.40
PYGM P11217 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
RIPK2 O43353 1/20 0.39
ABCB11 O95342 1/20 0.39
ABL1 P00519 1/20 0.39
RAF1 P04049 1/20 0.39
NR3C1 P04150 1/20 0.39
RET P07949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26074296 0.89 CSF1R (0.46) FLT3CSF1RCTSAANO1NPC1
SCHEMBL26074375 0.87 NPC1 (0.47) FLT3CSF1RANO1NPC1RAB9A
SCHEMBL26074472 0.86 DDR1 (0.45) FLT3ANO1GRM4PYGLPYGM
SCHEMBL26074277 0.83 CSF1R (0.47) FLT3CSF1RCTSANPC1RAB9A
SCHEMBL26074275 0.79 CSF1R (0.56) FLT3CSF1RANO1NPC1RAB9A
SCHEMBL26074348 0.79 BRAF (0.40) ANO1NPC1RAB9ARAF1BRAF
SCHEMBL26074273 0.78 GRM4 (0.57) FLT3CSF1RANO1NPC1RAB9A
SCHEMBL26075548 0.77 BRAF (0.44) ANO1GRM4PYGLPYGMRAF1
SCHEMBL26075764 0.77 RAF1 (0.43) ANO1RAF1BRAF
SCHEMBL26074471 0.75 CSF1R (0.46) FLT3CSF1RCTSANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 FLT3 19/4885CSF1R 1249/4885CTSA 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.